<DOC>
	<DOCNO>NCT02753543</DOCNO>
	<brief_summary>This single arm , prospective trial evaluate efficacy safety Chidamide combination previous chemotherapy peripheral T cell lymphoma patient achieve complete response 3 cycle chemotherapy interim evaluation .</brief_summary>
	<brief_title>Chidamide Plus Chemotherapy Treatment Peripheral T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<criteria>Pathologically verified peripheral Tcell lymphoma , partial response stable disease 3 cycle CEOP ( cyclophosphamide , epirubicin doxorubicin , vincristine prednisone ) CEOP ( cyclophosphamide , vincristin , epirubicin prednisone ) /IVE ( ifosfamide , epirubicin , etoposide ) /GDP ( Gemcitabine , Cisplatinum , Dexamethasone ) Age ≧16 year , ≦75 year ECOG ( Eastern Cooperative Oncology Group ) =0,1,2 No previous history malignancy Radiologically measurable disease Life expectancy &gt; 6 month Informed consent Active infectious disease require general antibiotic , antifungal antivirus therapy Lab enrollment ( unless cause lymphoma ) Neutrophile &lt; 1.5*10^9/L Platelet &lt; 75*10^9/L Hemoglobulin &lt; 90g/L ALT ( alanine aminotransferase ) AST ( aspartate aminotransferase ) &gt; 2*ULN , AKP ( alkaline phosphatase ) bilirubin &gt; 1.5*ULN ( upper limit normal ) Creatinine &gt; 1.5*ULN Other uncontrollable medical condition may may interfere participation study Not able comply protocol mental unknown reason Pregnant lactation HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>